Pub. Date : 2000 Sep 8
PMID : 10880513
10 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. | Dexamethasone | interleukin 6 | Homo sapiens |
| 2 | Our previous studies have shown that activation of a related adhesion focal tyrosine kinase (RAFTK) (also known as Pyk2) is required for dexamethasone (Dex)-induced apoptosis in multiple myeloma (MM) cells and that human interleukin-6 (IL-6), a known growth and survival factor for MM cells, blocks both RAFTK activation and apoptosis induced by Dex. | Dexamethasone | interleukin 6 | Homo sapiens |
| 3 | Our previous studies have shown that activation of a related adhesion focal tyrosine kinase (RAFTK) (also known as Pyk2) is required for dexamethasone (Dex)-induced apoptosis in multiple myeloma (MM) cells and that human interleukin-6 (IL-6), a known growth and survival factor for MM cells, blocks both RAFTK activation and apoptosis induced by Dex. | Dexamethasone | interleukin 6 | Homo sapiens |
| 4 | Our previous studies have shown that activation of a related adhesion focal tyrosine kinase (RAFTK) (also known as Pyk2) is required for dexamethasone (Dex)-induced apoptosis in multiple myeloma (MM) cells and that human interleukin-6 (IL-6), a known growth and survival factor for MM cells, blocks both RAFTK activation and apoptosis induced by Dex. | Dexamethasone | interleukin 6 | Homo sapiens |
| 5 | Our previous studies have shown that activation of a related adhesion focal tyrosine kinase (RAFTK) (also known as Pyk2) is required for dexamethasone (Dex)-induced apoptosis in multiple myeloma (MM) cells and that human interleukin-6 (IL-6), a known growth and survival factor for MM cells, blocks both RAFTK activation and apoptosis induced by Dex. | Dexamethasone | interleukin 6 | Homo sapiens |
| 6 | Our previous studies have shown that activation of a related adhesion focal tyrosine kinase (RAFTK) (also known as Pyk2) is required for dexamethasone (Dex)-induced apoptosis in multiple myeloma (MM) cells and that human interleukin-6 (IL-6), a known growth and survival factor for MM cells, blocks both RAFTK activation and apoptosis induced by Dex. | Dexamethasone | interleukin 6 | Homo sapiens |
| 7 | Our previous studies have shown that activation of a related adhesion focal tyrosine kinase (RAFTK) (also known as Pyk2) is required for dexamethasone (Dex)-induced apoptosis in multiple myeloma (MM) cells and that human interleukin-6 (IL-6), a known growth and survival factor for MM cells, blocks both RAFTK activation and apoptosis induced by Dex. | Dexamethasone | interleukin 6 | Homo sapiens |
| 8 | However, the mechanism whereby IL-6 inhibits Dex-induced apoptosis is undefined. | Dexamethasone | interleukin 6 | Homo sapiens |
| 9 | We show that IL-6 triggers selective activation of SHP2 and its association with RAFTK in Dex-treated MM cells. | Dexamethasone | interleukin 6 | Homo sapiens |
| 10 | Moreover, overexpression of dominant negative SHP2 blocked the protective effect of IL-6 against Dex-induced apoptosis. | Dexamethasone | interleukin 6 | Homo sapiens |